Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neutropenia 2Hematologic Neoplasms 2Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Pulmonary Arterial Hypertension 1Pneumonia 1Pancreatic Neoplasms 1Pancreatic Diseases 1Pain 1Other Infectious Diseases 1Migraine Disorders 1Menorrhagia 1Meningitis, Bacterial 1Meningitis 1Intraabdominal Infections 1Influenza, Human 1Inflammation 1Infections 1Hypokalemia 1Hypertension 1Hyperaldosteronism 1Herpes Simplex 1

Interventions

ceftolozane 1Tazobactam 1Piperacillin, Tazobactam Drug Combination 1Meropenem 1Cefepime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Other Infectious Diseases × Piperacillin, Tazobactam Drug Combination × Clear all
NCT03485950 2022-03-15

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 33 charts

Other Infectious Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡